TNF Inhibitors Market Size (2024 - 2029)

TNF Inhibitors Market Analysis

The TNF Inhibitors Market size is estimated at USD 39.67 billion in 2024, and is expected to reach USD 47.32 billion by 2029, growing at a CAGR of 3.59% during the forecast period (2024-2029).

COVID-19 had an unprecedented impact on the market's growth due to disruption in the supply chain across the globe. TNF inhibitors found large applications in the treatment of COVID-19, thereby impacting the demand. For instance, the Journal of American Medical Association article published in October 2021 concluded that TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with immune-mediated inflammatory diseases. Thus, studies that demonstrate the effectiveness of the TNF monotherapy treatment in COVID-19 patients had a significant impact on the growth of the market. In addition, the demand for TNF inhibitors during the post-pandemic period is expected to remain intact due to the emergence of various mutant strains of the SARS-CoV-2 virus and the rising focus on auto-immune disease treatments, thereby contributing to the growth of the market over the forecast period.

The major factors attributing to the growth of the market are the rise in the global prevalence of autoimmune disorders such as (RA) Rheumatoid Arthritis, Inflammatory Bowel Disorder, Psoriasis, and Crohn's disease coupled with the increase in the aged population. For instance, As per the International Foundation for Gastrointestinal Disorders (IFFGD) report published in 2021, around 10 to 15% of the population is affected by irritable bowel syndrome worldwide, including approximately 25 to 45 million people suffering from the disease in the United States. Also, according to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD was around 7 million worldwide annually. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. Such increasing incidences of various auto-immune diseases are expected to drive the demand for effective treatment and therapeutics such as TNF inhibitors, thereby contributing to the market's growth over the forecast period.

Furthermore, the approval of the products by the regulatory authorities to provide safe and effective therapeutics also contributes to the market's growth. For Instance, in December 2021, Coherus BioSciences, Inc. received United States FDA approval for YUSIMRY (adalimumab-aqvh), formerly CHS-1420, a Humira (adalimumab) biosimilar product. YUSIMRY is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.

Thus, owing to the abovementioned factors, the market is anticipated to project growth over the forecast period. However, the high risk of complications coupled with challenges while in the development stage and expensive patented biologics may hinder the market's growth.

TNF Inhibitors Industry Segmentation

As per the scope of the report, TNF-alpha is the first element in the cytokine cascade, which plays a vital role in systemic inflammation and is identified as the cause of various autoimmune diseases. TNF inhibitors are drugs that reverse the damage caused by autoimmune diseases. 

The TNF Inhibitors Market is segmented by Drug class (Adalimumab, Infliximab, Rituximab, and Others), Indication (Rheumatoid Arthritis, Crohn's Disease, Psoriasis, and Others), End-user (Hospital Pharmacies, Specialty Pharmacies, and Online Pharmacies) Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the abovementioned segments.